All articles tagged with #zenkuda
Kodiak Sciences shares surged nearly 178% after its Phase 3 Daybreak trial results showed that both Zenkuda and tabirafusp-ted matched the efficacy of aflibercept (Eylea) for wet age-related macular degeneration. The company plans to file for FDA approval of Zenkuda in the fourth quarter of 2026, citing data that allows for extended dosing intervals.
Kodiak Sciences stock jumped 178% after its two eye drugs, Zenkuda and tabirafusp-ted, matched Regeneronās Eylea in a Phase 3 trial for wet age-related macular degeneration. Zenkuda allowed over half of patients to receive injections only once every six months, compared to every eight weeks for Eylea. The company plans to file for FDA approval of Zenkuda in the fourth quarter of 2026.
Kodiak Sciences shares jumped 128% after its Phase 3 DAYBREAK trial showed its drug Zenkuda matched the efficacy of aflibercept for wet age-related macular degeneration. The company plans to file for FDA approval in Q4 2026.